EFFICACY OF PROTHROMBIN-COMPLEX CONCENTRATES IN HEMOPHILIACS WITH ANTIBODIES TO FACTOR-VIII - A MULTI-CENTER THERAPEUTIC TRIAL

被引：238
|
作者：
LUSHER, JM [1 ]
SHAPIRO, SS [1 ]
PALASCAK, JE [1 ]
RAO, AV [1 ]
LEVINE, PH [1 ]
BLATT, PM [1 ]
机构：
[1] NHLBI,BETHESDA,MD 20205
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 1980年 / 303卷 / 08期
关键词：
D O I：
10.1056/NEJM198008213030803
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：421 / 425
页数：5
相关论文
共 29 条
  • [21] Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VIII and IX inhibitors
    Barthels, M
    THROMBOSIS RESEARCH, 1999, 95 (04) : S31 - S38
  • [22] THE PROBLEM OF THERAPEUTIC EQUIVALENCE WITH PAIRED QUALITATIVE DATA - AN EXAMPLE FROM A CLINICAL-TRIAL USING HEMOPHILIACS WITH AN INHIBITOR TO FACTOR-VIII
    LEE, ML
    LUSHER, JM
    STATISTICS IN MEDICINE, 1991, 10 (03) : 433 - 441
  • [23] AIDS RETROVIRUS ANTIBODIES IN HEMOPHILIACS TREATED WITH FACTOR-VIII OR FACTOR-IX CONCENTRATES, CRYOPRECIPITATE, OR FRESH-FROZEN PLASMA - PREVALENCE, SEROCONVERSION RATE, AND CLINICAL CORRELATIONS
    RAGNI, MV
    TEGTMEIER, GE
    LEVY, JA
    KAMINSKY, LS
    LEWIS, JH
    SPERO, JA
    BONTEMPO, FA
    HANDWERKLEBER, C
    BAYER, WL
    ZIMMERMAN, DH
    BRITZ, JA
    BLOOD, 1986, 67 (03) : 592 - 595
  • [24] Evaluation of whole blood clotting activity of recombinant factor VIII Fc fusion protein by ROTEM analysis in a multi-center Phase 3 clinical trial
    Sommer, J.
    Driessler, F.
    Miguelino, M.
    Powell, J.
    Luk, A.
    Pierce, G. F.
    Jiang, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 39 - 39
  • [25] Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study
    Li, Changgang
    Zhang, Xinsheng
    Zhao, Yongqiang
    Wu, Runhui
    Hu, Qun
    Xu, Weiqun
    Sun, Jing
    Yang, Renchi
    Li, Xiaojing
    Zhou, Rongfu
    Lian, Shinmei
    Gu, Jian
    Wu, Junde
    Hou, Qingsong
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (07) : 1223 - 1230
  • [26] Trial in Progress: An Open-Label, Multi-Center, First in Human, Phase 1/2a Trial to Evaluate the Safety and Preliminary Efficacy of Autologous Tolerogenic Dendritic Cells Ex Vivo Loaded with Recombinant Factor VIII (FVIII) in Adults with Congenital Hemophilia a (HA) with Neutralizing Antibodies to FVIII and Having Failed Immune Tolerance Induction (ITI)
    Astermark, Jan
    Ljung, Rolf
    Karlsson, Eva
    Xie, Hanjing
    BLOOD, 2022, 140 : 12733 - 12734
  • [27] An open-label, multi-center extension study to assess the efficacy and safety of a plasma-derived von willebrand factor/factor VIII (VWF/FVIII) concentrate in pediatric, adolescent, and adult subjects with von willebrand disease
    Lissitchkov, T.
    Klukowska, A.
    Kuliczkowski, K.
    Buevich, E.
    Auerswald, G.
    Stasyshyn, O.
    Seifert, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 495 - 496
  • [28] A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells
    Knaub, Sigurd
    Tiede, Andreas
    Lissitchkov, Toshko
    Valentino, Leonard A.
    Powell, Jerry Sherman
    Manco-Johnson, Marilyn J.
    BLOOD, 2011, 118 (21) : 1423 - 1423
  • [29] A phase III open-label, multi-center study with a plasma-derived von Willebrand factor/factor VIII concentrate to assess the pharmacokinetics, efficacy, and safety in pediatric subjects with von Willebrand disease (SWIFTLY-VWD study)
    Auerswald, G.
    Khayat, C.
    Stasyshyn, O.
    Iosova, G.
    Ramasheuskaya, I
    Ruano, M. J. L.
    Seifert, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 735 - 735
123